证券代码：003017 证券简称：大洋生物 公告编号：2025-091 浙江大洋生物科技集团股份有限公司 关于公司对子公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、浙江大洋生物科技集团股份有限公司（以下简称"公司"）及子公司累 计担保总余额为 33,650.00 万元（包含本次担保金额），占公司最近一期（2024 年 12 月 31 日）经审计净资产的比例为 31.95%。本次担保事项在公司 2025 年度 担保额度预计范围内。 2、公司及子公司未对合并报表范围外的公司提供担保。 3、公司及子公司未发生逾期担保、涉及诉讼的担保及因担保被判决败诉而 应承担损失的情况。 公司于 2025 年 8 月 22 日召开的第六届董事会第五次会议及 2025 年 9 月 12 日召开的 2025 年第二次临时股东大会，审议通过了《关于对公司及子公司增加 担保预计额度的议案》。同意对公司及子公司向银行等金融机构提供的担保额度 增加不超过人民币 30,000.00 万元，担保范围包括但不限于申请综合授信、借款、 保函、承兑汇票、固定资产贷款 ...

Group 1 - The company is planning to construct an 800-ton hydrochloric acid aminophenol production facility, which will lead to the shutdown of the existing 600-ton production line [2] - After the completion of the new facility, the total production capacity will not be 1400 tons, as the existing line will cease operations [2]

Company Overview - Zhejiang Dayang Biological Technology Group Co., Ltd. is located in Jiande City, Hangzhou, Zhejiang Province, and was established on January 1, 1976. The company was listed on October 26, 2020. [2] - The main business involves the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials. The revenue composition is as follows: inorganic salt products 69.91%, veterinary raw materials 18.35%, fluorine chemical products 7.46%, and other products 4.28%. [2] Stock Performance - As of September 16, the stock price of Dayang Biological fell by 2.10% to 33.58 CNY per share, with a trading volume of 42.01 million CNY and a turnover rate of 1.78%. The total market capitalization is 2.821 billion CNY. [1] - Year-to-date, the stock price has increased by 83.26%, but it has decreased by 7.11% in the last five trading days. Over the last 20 days, the stock price has risen by 0.33%, and over the last 60 days, it has increased by 31.22%. [2] Financial Performance - For the first half of 2025, Dayang Biological achieved operating revenue of 499 million CNY, representing a year-on-year growth of 14.20%. The net profit attributable to the parent company was 50.51 million CNY, with a year-on-year increase of 60.66%. [2] - The company has distributed a total of 168 million CNY in dividends since its A-share listing, with cumulative distributions of 97.57 million CNY over the past three years. [3] Shareholder Information - As of June 30, the number of shareholders reached 14,200, an increase of 58.33% compared to the previous period. The average number of circulating shares per person is 4,954, which is a decrease of 35.82% from the previous period. [2] Industry Classification - Dayang Biological is classified under the Shenwan industry category of basic chemicals, specifically in chemical raw materials and inorganic salts. The company is associated with several concept sectors, including fertilizers, fluorine chemicals, biological pesticides, and share buybacks. [2]

Market Overview - On September 15, the chemical raw materials sector declined by 0.16% compared to the previous trading day, with Zhenhua Co., Ltd. leading the decline [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - Notable gainers in the chemical raw materials sector included: - Longbai Group (002601) with a closing price of 19.62, up 5.09% and a trading volume of 667,300 shares, totaling 1.314 billion yuan [1] - ST Yatai (000691) with a closing price of 7.81, up 4.97% and a trading volume of 101,400 shares, totaling 79.1972 million yuan [1] - Jinhai Titanium Industry (000545) with a closing price of 3.69, up 4.53% and a trading volume of 1,184,600 shares, totaling 435 million yuan [1] - Major decliners included: - Zhenhua Co., Ltd. (603067) with a closing price of 17.90, down 4.33% and a trading volume of 180,800 shares, totaling 329 million yuan [2] - Sanyou Chemical (600409) with a closing price of 5.78, down 3.02% and a trading volume of 368,900 shares, totaling 216 million yuan [2] - Jinniu Chemical (600722) with a closing price of 7.09, down 2.88% and a trading volume of 319,900 shares, totaling 228 million yuan [2] Capital Flow - The chemical raw materials sector experienced a net outflow of 398 million yuan from institutional investors, while retail investors saw a net inflow of 239 million yuan [2][3] - Notable capital flows included: - Huayi Group (600623) with a net inflow of 26.8479 million yuan from institutional investors [3] - Tianyuan Co., Ltd. (002386) with a net inflow of 25.0141 million yuan from institutional investors [3] - Xue Tian Salt Industry (600929) with a net inflow of 21.3913 million yuan from institutional investors [3]

Group 1 - The core point of the news is the performance and financial details of Zhejiang Dayang Biological Technology Group Co., Ltd, which saw a stock price increase of 5.02% to 35.15 CNY per share, with a total market capitalization of 2.953 billion CNY [1] - The company was established on January 1, 1976, and went public on October 26, 2020, focusing on the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials [1] - The revenue composition of the company is as follows: 69.91% from inorganic salt products, 18.35% from veterinary raw materials, 7.46% from fluorine-containing chemicals, and 4.28% from other products [1] Group 2 - From the perspective of fund holdings, one fund under Huaxia Fund has a significant position in Dayang Biological, specifically the Huaxia Steady Growth One-Year Holding Mixed A fund, which held 2,400 shares, accounting for 0.14% of the fund's net value [2] - The Huaxia Steady Growth One-Year Holding Mixed A fund was established on August 11, 2023, with a latest scale of 29.2614 million CNY, and has achieved a year-to-date return of 1.93% [2] - The fund manager, Song Yang, has been in the position for 8 years and 304 days, with the fund's total asset scale at 9.393 billion CNY, achieving a best return of 76.17% and a worst return of -13.01% during his tenure [2]

Core Viewpoint - On September 12, 2025, the company announced the election of Mr. Guan Weijun as the employee representative director of the sixth board of directors during the employee representative assembly [1] Group 1 - The employee representative assembly was held on September 12, 2025 [1] - The assembly involved democratic discussion and voting [1] - Mr. Guan Weijun was elected as the employee representative director [1]

Group 1 - The company, Dayang Bio (SZ 003017), held its sixth board meeting on September 12, 2025, to review various proposals, including the confirmation of the audit committee members and the convener [1] - For the first half of 2025, the company's revenue composition was 95.72% from the chemical industry and 4.28% from other sources [1] - As of the report date, Dayang Bio's market capitalization was 2.8 billion yuan [1]

证券代码：003017 证券简称：大洋生物 公告编号：2025-089 浙江大洋生物科技集团股份有限公司 关于公司 2024 年员工持股计划第一个解锁期届满 暨解锁条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 2、公司于 2024 年 9 月 10 日收到中国证券登记结算有限责任公司深圳分公 司下发的《证券过户登记确认书》，"浙江大洋生物科技集团股份有限公司回购专 用证券账户"所持有的 1,947,030 股公司股票已于 2024 年 9 月 9 日非交易过户 至"浙江大洋生物科技集团股份有限公司-2024 年员工持股计划"账户，过户股 份数量占公司总股本的 2.32%。具体内容详见公司于 2024 年 9 月 11 日在《证券 时报》《证券日报》《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于 2024 年员工持股计划非交易过户完成的公告》。 3、根据《公司 2024 年员工持股计划》的相关规定，本员工持股计划的存续 期为 36 个月，所获标的股票分两期解锁，锁定期分别为 12 个月、24 个月 ...

证券代码：003017 证券简称：大洋生物 公告编号：2025-090 浙江大洋生物科技集团股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日召开了 2025 年第二次临时股东大会，审议通过了《关于修订<公司章程>的 议案》。根据修订后的《公司章程》，公司董事会设职工代表董事一名。公司于 同日召开了职工代表大会，选举关卫军先生担任公司第六届董事会职工代表董事。 相关情况公告如下： 公司近日收到了非独立董事关卫军先生提交的辞职报告，因工作调整，关卫 军先生申请辞去公司第六届董事会非独立董事职务，辞去董事职务后仍担任公司 其他职务。关卫军先生辞去非独立董事职务不会导致公司董事会成员低于法定最 低人数，不会影响公司董事会的正常运行，亦不会对公司正常的经营发展产生影 响。 关卫军先生将继续遵守《上市公司董事和高级管理人员所持本公司股份及其 变动管理规则》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自 律监管指引第 1 号—— ...

2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会召开期间不存在增加、否决或变更提案的情形。 证券代码：003017 证券简称：大洋生物 公告编号：2025-086 浙江大洋生物科技集团股份有限公司 2、本次股东大会采取现场投票表决和网络投票表决相结合的方式进行。 一、会议召开和出席情况 1、股东大会届次：2025 年第二次临时股东大会 2、股东大会的召集人：公司董事会 3、会议主持人：公司董事长陈阳贵先生 4、会议召开的合法、合规性：本次股东大会会议的召集、召开程序符合《中 华人民共和国公司法》《上市公司股东大会规则》和《浙江大洋生物科技集团股 份有限公司章程》的有关规定。 5、会议召开日期和时间 （1）现场会议时间：2025 年 9 月 12 日下午 2:00 （2）网络投票时间：2025 年 9 月 12 日（星期五）。其中：通过深圳证券交 易所交易系统进行网络投票的具体时间为 2025 年 9 月 12 日（星期五） 9:15—9:25,9:30—11:30 和 13:00—15:00； ...